UNSPSC 51461545: Cetyl myristoleate

A supplement used for arthritis and joint pain treatment.

UNSPSC 51461545 Cetyl myristoleate (Commodity) describes a specific pharmaceutical ingredient, but recent state and local procurement activity under this code shows little relevant activity. The one recent opportunity identified, issued by the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) on January 20, 2026, is a Request for Proposal for generic multi-source pharmaceuticals and over-the-counter products generally, not for cetyl myristoleate as a discrete product line. The solicitation targets manufacturers of finished pharmaceutical products for distribution across participating state and local government facilities in Minnesota and Oregon, with awarded vendors required to supply through three authorized wholesalers and to maintain compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and FDA requirements.

The MMCAP RFP reflects a cooperative purchasing vehicle spanning multiple jurisdictions rather than a single state agency or county buyer. Proposals are due March 26, 2026, with evaluation weighted heavily toward price competitiveness (75 percent) and vendor performance on fixed pricing, administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee. Vendors must maintain commercial general liability insurance of $5 million per occurrence and demonstrate pricing flexibility through multiple structures including flat price, net price formats, or WAC-minus arrangements. The contract term runs two years for new respondents, with optional extensions at MMCAP's discretion. The source does not disclose award values or budget ranges, nor does it identify any set-aside designations for disadvantaged enterprises.